Susanne SchaffertBoard Director at Novo Holding, Incyte, Galapagos, Vetter, ARTBioSpeaker
Dr. Schaffert was the former President of Novartis Oncology and a member of the Novartis Executive Committee until April 2022. In this function she was leading one of the broadest portfolios in Oncology across hematology and solid tumors. Amongst other achievements, she was responsible to market and provide access to the first CAR-T cell therapy in hematology across 34 countries and launching the first 2 radio ligand therapies ever in solid tumors. She was leading 10.000 associates fully dedicated to driving solutions in cancer treatment across 80 countries, delivering annual sales returns of USD 15bn.
Susanne joined Novartis Germany in 1995 as a sales representative and has held a series of positions in Sales & Marketing and General management with increasing responsibilities in both National and Global functions such as Global Brand Director, Head of Marketing Oncology, Germany, BU Head Oncology Germany, and Head of Northern & Central Europe for Novartis Oncology. She also served as Head of Investor Relations, as Head of Europe Oncology and as President and Chairman of Accelerated Advanced Applications, AAA, a Novartis company.
Susanne is an independent director on the board of Incyte Corporation, Delaware, US and serves as board member and member of the Advisory Group at Novo Holdings, Denmark. She is independent director on the board of Galapagos, Belgium, on the board of ARTBio, USA as well as on the board of Vetter, Germany. In addition, she serves as a member of the Executive Education Senate Committee of the University St. Gallen, Switzerland.
Susanne holds a PhD in Chemistry with honors from University of Erlangen (Germany).
She was recognized as one of the Top 100 Most Powerful Women International on the Fortune List in 2019 and 2020